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Background: Cyclins and their catalytic partners, the cyclin-dependent kinases
(Cdks), function as key regulators of the eukaryotic cell cycle. Specific
cyclin–Cdk complexes are active at successive stages during the cell cycle and
control cell-cycle progression by phosphorylating specific target proteins, most
of which have not yet been identified. B-Myb, a conserved member of the Myb
oncoprotein family, is a sequence-specific DNA-binding protein expressed in
virtually all proliferating mammalian cells. Increasing evidence suggests that B-
Myb plays an important role during the late G1 and early S phases of the cell
cycle. In this study, we have examined the regulation of B-Myb activity by
cyclin–Cdks.
Results: We found that the transcriptional transactivation potential of B-Myb was
repressed by a regulatory domain located at the carboxyl terminus of the protein.
Coexpression of B-Myb and cyclin A relieved this repression by phosphorylation
of B-Myb in its carboxy-terminal region. Tryptic phosphopeptide mapping
revealed that endogenous B-Myb was phosphorylated in cells undergoing S
phase.
Conclusions: This work provides evidence for a link between the Myb
oncoprotein family and the cell-cycle machinery. We have shown that the
carboxyl terminus of B-Myb acts as a cell-cycle sensor that regulates the
transactivation function of B-Myb. Moreover, our studies have identified B-Myb
as a target of cyclin A–Cdk2 and have indicated that B-Myb activity is regulated
by phosphorylation mediated by cyclin A–Cdk2.
Background
In recent years, the cyclins and their catalytic partners, the
cyclin-dependent kinases (Cdks), have been identified as
key regulators of the eukaryotic cell cycle (see [1], and
references therein). It is generally accepted that different
cyclin–Cdk complexes appear at different times during
the cell cycle and control cell-cycle progression by
phosphorylating specific target proteins. In particular,
complexes of cyclin D1 with Cdk4 or Cdk6 have been
shown to play an important role at the ‘restriction point’ in
the G1 phase of the cell cycle at which cells become com-
mitted to the next mitotic cycle, whereas cyclin E–Cdk2
complexes are most critical for the transition from G1 to S
phase and cyclin A–Cdk2 complexes are required during S
phase [2–12]. Although certain cyclin–Cdk target proteins,
such as the retinoblastoma protein [13], have been studied
in great detail, many targets, particularly those regulated
by the kinases associated with cyclins A and E, remain to
be identified.
B-myb is a member of the myb proto-oncogene family that is
conserved among vertebrates [14–17]. The B-Myb protein
is a sequence-specific DNA-binding protein which differs
from other members of the Myb family (c-Myb and A-Myb)
in that it has extremely weak or undetectable transactivation
activity [14–19]. This lack of transactivation activity was ini-
tially taken to mean that B-Myb acts as an inhibitor of other
members of the Myb family [16,19]. Increasing evidence
now suggests that B-Myb plays a general role during cell-
cycle progression in most, if not all, cell types. 
In contrast to c-myb and A-myb, the functions of which
appear to be restricted to specific cell types, B-myb is
expressed in virtually all proliferating cells and tissues
[14–17,20,21]. During embryonic development of the
mouse, the expression of B-myb is tightly linked to the
proliferative activity of cells and tissues [21]. B-myb
expression is controlled by the transcription factor E2F,
and expression reaches its maximum at the G1–S-phase
boundary and is maintained at this high level during S
phase of the cell cycle [22,23]. Overexpression of B-myb
can allow cells to escape the cell-cycle arrest that is
induced by overexpression of the oncoprotein p53 and
mediated by the Waf1/Cip1 protein [24]. Interestingly,
this effect of B-myb does not involve restoration of p53-
dependent inhibition of cyclin E–Cdk2 kinase activity,
raising the possibility that B-myb acts at a later stage than
cyclin E–Cdk2 during cell-cycle progression.
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Here, we have examined the regulation of B-Myb activity
by a number of components of the cell-cycle machinery.
We show that the transactivation potential of B-Myb is
repressed by a regulatory domain located at the carboxyl
terminus of the protein and that the inhibitory effect of
this domain is relieved by phosphorylation of B-Myb
induced by cyclin A–Cdk2. Our studies therefore identify
B-Myb as a target for cyclin A–Cdk2 kinase activity and
indicate that B-Myb activity is regulated by phosphoryla-
tion. Furthermore, our work provides evidence for a link
between the Myb family and the cyclins and Cdks which
constitute the cell-cycle machinery.
Results
A cyclin-dependent inhibitory domain at the carboxyl
terminus of B-Myb
The carboxy-terminal domain of c-Myb has previously
been implicated in repressing the activity of the c-Myb
protein [25–27]. To investigate whether the apparent lack
of transactivation activity of B-Myb is due to inhibition
mediated by the protein’s carboxyl terminus, we first
assessed the transactivation potential of carboxy-terminally
deleted B-Myb. Consistent with previous studies [16,19],
full-length B-Myb was virtually inactive, whereas truncated
B-Myb (B-Myb-D3) activated a Myb-responsive reporter
gene containing the herpes simplex virus thymidine kinase
promoter fused to three Myb-binding sites (Fig. 1). Further
deletion of an acidic region located in the center of B-Myb
produced an inactive protein (B-Myb-DPvu). These results
suggested that the transactivation activity of B-Myb is
repressed by an inhibitory domain located at the carboxyl
terminus of the protein. 
To confirm this result in a different promoter context, we
examined the transactivation potential of GAL4–B-Myb
fusion proteins; these proteins consisted of B-Myb either
including its carboxy-terminal domain (GAL4–B-Myb-fl)
or lacking this domain (GAL4–B-Myb-D3), fused to the
DNA-binding domain of the yeast GAL4 protein. We used
the adenovirus E4 promoter fused to five copies of the
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Stimulation of B-Myb transactivation activity by cyclin A. (a) Full-length
and deleted mouse B-Myb proteins: DBD, Myb DNA-binding domain;
the GAL4 DNA-binding domain is shown in black. (b–f) COS-7 cells
were cotransfected with expression vectors for full-length or deleted
mouse B-Myb or GAL4–B-Myb or mouse c-Myb (5 mg), cyclins A, D1
or E (3 mg), the Myb-responsive reporter gene p3xATk-Luc (5 mg;
b,d–f) or the GAL4-responsive reporter gene pG5E4-38-Luc (5 mg; c),
and the b-galactosidase reference plasmid pCMVb (0.5 mg) to monitor
the transfection efficiency. Control transfections contained equivalent
amounts of empty expression vector pCDNA3. Cells were analyzed for
luciferase and b-galactosidase activities 24 h after transfection. The
luciferase activity in the absence of Myb was designated as 1. Thin
lines show standard deviations. Also shown on the right of (b,c) are
western blots of COS-7 cells transfected with 5 mg each of the
indicated B-Myb expression vectors.
GAL4-binding site as the GAL4-responsive test promoter
driving reporter gene expression. In accordance with the
results in Figure 1a,b, the truncated fusion protein acti-
vated a GAL4-dependent reporter gene, whereas the full-
length fusion protein was virtually inactive, confirming the
existence of an inhibitory domain at the carboxyl terminus
of B-Myb (Fig. 1c). 
Several potential phosphorylation sites for cell-cycle-
regulated kinases are present in the carboxy-terminal half
of B-Myb, raising the possibility that the carboxyl terminus
of B-Myb acts as a cell-cycle-regulated inhibitory domain.
In order to examine whether the activity of B-Myb is
indeed controlled by cell-cycle-dependent phosphoryla-
tion, we cotransfected expression vectors for full-length B-
Myb with expression vectors for different cyclins and
determined the resulting transactivation potential of B-
Myb. Interestingly, full-length B-Myb activated the Myb-
responsive reporter when coexpressed with cyclin A, but
not when coexpressed with cyclins B1, B2, D1 or E (Fig.
1d and data not shown). Transactivation by another Myb
family member, c-Myb, was not affected by cyclin A (Fig.
1e), indicating that the stimulation of B-Myb activity by
cyclin A is specific. Finally, the activity of truncated B-
Myb (B-Myb-D3) was not increased by cyclin A (Fig. 1f),
consistent with the idea that cyclin A counteracts the
inhibitory effect of the carboxy-terminal domain.
Cyclin-dependent regulation of B-Myb activity does not
require the B-Myb DNA-binding domain
To confirm the specificity of the cyclin A-dependent
increase in transactivation by B-Myb, we examined the
effect of cyclin A coexpression on the activity of a GAL4–B-
Myb fusion protein, using a GAL4-dependent reporter gene
to monitor transactivation. This fusion protein, which has a
deletion of the Myb DNA-binding domain and therefore
lacks Myb-specific DNA-binding activity, was also strongly
stimulated by cyclin A (Fig. 2). As a control, we performed a
similar experiment using a GAL4–Myc fusion protein, to
provide a completely different GAL4-dependent transacti-
vator; the activity of the GAL4–Myc protein was not
affected by cyclin A coexpression (Fig. 2). This experiment
therefore shows that the effect of cyclin A on B-Myb is spe-
cific and is not dependent on a particular reporter gene
assay system. Furthermore, because this experiment used a
fusion protein that had the GAL4 DNA-binding domain in
place of the B-Myb DNA-binding domain, it shows that
cyclin A does not act by simply increasing the binding of B-
Myb to Myb-binding sites.
Cyclin A coexpression induces a slow-migrating
phosphorylated form of B-Myb
The stimulatory effect of coexpressed cyclin A on B-Myb
activity raised the possibility that B-Myb might be
phosphorylated by a cyclin A–Cdk complex. To address
this possibility, B-Myb was coexpressed with different
cyclins and the mobility of the B-Myb protein was ana-
lyzed by SDS gel electrophoresis and western
immunoblotting. Figure 3a shows that a slow-migrating
form of B-Myb was induced by coexpression of cyclin A
but not by coexpression of other cyclins. Immunoprecipita-
tion of cyclin–Cdk complexes from the transfected cells,
followed by in vitro kinase assays using the synthetic
peptide KIRSPRRFIGSPRTPVSPVK (single letter
amino-acid code) as a model substrate, showed that kinase
activity was indeed induced by expression of the different
cyclins (data not shown). The inability of cyclins D1 and E
to induce a slow-migrating form of B-Myb is therefore not
because these cyclins lack associated kinase activity but
instead reflects a specific interaction of cyclin A–Cdk2 with
B-Myb. Cyclin A did not affect the mobility of carboxy-
terminally truncated B-Myb or of c-Myb (Figs. 3b,c),
Research Paper  Phosphorylation of B-Myb by cyclin A–Cdk2 Ziebold et al. 255
Figure 2
Stimulation of B-Myb transactivation activity by coexpressed cyclin A
does not require the Myb DNA-binding domain. COS-7 cells were
cotransfected with expression vectors encoding the GAL4–B-Myb
fusion protein (shown schematically above the histogram) or encoding
a GAL4–Myc fusion protein (5 mg each), plus cyclin A (3 mg), the
GAL4-responsive reporter gene pG5E4-38Luc (5 mg) and the b-
galactosidase reference plasmid pCMVb (0.5 mg). Control
transfections contained equivalent amounts of empty expression vector
pCDNA3. Cells were analyzed as decribed in Fig. 1 legend.
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confirming that this mobility effect of cyclin A is specific
for full-length B-Myb. 
During S phase of the cell cycle, the naturally active
kinase partner of cyclin A is Cdk2 [3,5,7,8]. To assess
whether the endogenous Cdk2 present in the transfected
cells was involved in the effect of cyclin A on B-Myb, we
coexpressed B-Myb and cyclin A with increasing amounts
of a kinase-negative mutant form of Cdk2, referred to as
Cdk2-R33 (U. Deuschle and S.F., unpublished observa-
tions). We observed that Cdk2-R33 suppressed the
appearance of the slow-migrating form of B-Myb, proba-
bly by titrating out the cyclin that would otherwise bind to
endogenous wild-type kinase (Fig. 3d). This is consistent
with the idea that the cyclin A–Cdk2 complex is responsi-
ble for the phosphorylation of B-Myb. To examine further
whether the change in the electrophoretic mobility of B-
Myb induced by cyclin A was caused by phosphorylation,
we performed an in vitro phosphatase treatment experi-
ment. As shown in Figure 3e, treatment with potato acid
phosphatase (PAP) converted the retarded form of B-Myb
into a faster migrating form, confirming that the cyclin A-
mediated effect observed on the pattern of electrophoretic
mobility of B-Myb was due to phosphorylation.
To demonstrate the phosphorylation of B-Myb directly, B-
Myb was coexpressed with cyclin A, labeled with 32P-
orthophosphate in vivo and immunoprecipitated. As shown
in Figure 4a, the amount of phosphate label incorporated
into B-Myb in the presence of cyclin A was much higher
than in its absence, indicating that the phosphorylation of
B-Myb was strongly increased by cyclin A. A low level of
phosphorylation of B-Myb in the absence of cotransfected
cyclin A was visible on longer exposures of the gel shown
in Figure 4a. This phosphorylation was presumably medi-
ated by endogenous cyclin A–Cdk2. The results presented
in Figure 4 clearly show that coexpression of cyclin A
strongly induces phosphorylation of B-Myb.
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Cyclin A induces a slow-migrating form of B-Myb. (a–d) Expression
vectors for full-length or truncated mouse B-Myb or c-Myb (5 mg) and
for cyclins A, D1 or E (3 mg) were cotransfected into COS-7 cells, as
indicated. To monitor the transfection efficiency, the b-galactosidase
reporter gene pCMVb (1 mg) was included in each transfection. Myb
proteins were analyzed by SDS–PAGE and western blotting 24 h after
transfection. In (d), lanes 4 and 5 show transfections which contained
additionally 1 mg (lane 4) or 3 mg (lane 5) expression vector encoding
a kinase-negative Cdk2 mutant (dnCdk2). The positions of the 97 kDa
and 116 kDa size markers from the blot shown in (a) are indicated at
the left. (e) COS-7 cells cotransfected with expression vector for full-
length B-Myb (8 mg), with or without cyclin A (4 mg), were labeled with
35S-methionine and immunoprecipitated with anti-B-Myb antiserum.
Aliquots of the immunoprecipitate were treated with potato acid
phosphatase (PAP) as described [38], and analyzed by SDS–PAGE
and autoradiography. Control incubations using phosphatase
inactivated by treatment with sodium orthovanadate and b glycerol
phosphate or by heat did not lead to a change of the electrophoretic
mobility pattern of B-Myb (data not shown).
Figure 4
Cyclin A-dependent phosphorylation of B-Myb. COS-7 cells
cotransfected with an expression vector encoding full-length B-Myb
(5 mg), with or without a cyclin A expression vector (3mg), were labeled
with 32P-orthophosphate. Cell extracts were analyzed by
immunoprecipitation (IP) with antibodies specific for B-Myb, followed by
SDS–PAGE and autoradiography. The amounts of immunoprecipitate
loaded onto the gel (a) were adjusted such that equal amounts of B-
Myb protein were present, as assessed by western blot (b).
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– Cyclin A     + Cyclin A – Cyclin A    + Cyclin A
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In order to examine whether B-Myb is a direct target of
cyclin A–Cdk2, we expressed the carboxy-terminal half of
B-Myb as a bacterial glutathione S-transferase fusion
protein, subjected it to kinase reactions in vitro using
immunopurified cyclin A–Cdk2, and compared it by two-
dimensional tryptic phosphopeptide analysis with B-Myb
phosphorylated in vivo. As illustrated in Figure 5c, bacterial
B-Myb could be phosphorylated in vitro using immunopu-
rified cyclin A–Cdk2 and yielded a number of tryptic phos-
phopeptides, the most prominent of which comigrated
with peptides obtained from B-Myb labeled in vivo (Fig.
5b). Note that a low level of phosphorylation of B-Myb also
occurred in the absence of cotransfected cyclin A (Fig. 5a):
we attribute these phosphorylations to the presence of
endogenous cyclin A–Cdk2 in the transfected cells. This
interpretation is supported by the finding that this basal
level of phosphorylation could be decreased by cotransfec-
tion of a dominant-negative mutant of Cdk2 (data not
shown). Taken together, the results presented in Figures 4
and 5 show that cyclin A strongly induces the phosphoryla-
tion of B-Myb at a number of sites, at least some of which
are also phosphorylated by cyclin A–Cdk2 in vitro. We con-
clude that B-Myb is a direct target for cyclin A–Cdk2. 
Phosphorylated B-Myb is present during S phase
We next investigated whether phosphorylation of B-Myb
also occurs in nontransfected cells. Swiss 3T3 fibroblasts
were synchronized by serum starvation, labeled with 32P-
orthophosphate and their proteins used for immunoprecip-
itation experiments. A phosphorylated form of B-Myb that
had the same electrophoretic mobility as the slow-migrat-
ing form of the protein induced by coexpression with
cyclin A could be specifically immunoprecipitated with
anti-B-Myb antiserum from S-phase cells, but not from
growth-arrested cells (data not shown). A similar form of
endogenous B-Myb that was sensitive to phosphatase
treatment has also been described in a recent report [28];
our data directly demonstrate the phosphorylation of
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Figure 5
Two-dimensional tryptic phosphopeptide
analysis of mouse B-Myb phosphorylated in
vivo and in vitro. COS-7 cells transfected with
expression vectors for (a) full-length B-Myb
(5 mg) or (b) B-Myb (5 mg) and cyclin A
(3 mg) were labeled for 5 h with 32P-labeled
orthophosphate. B-Myb was isolated by
immunoprecipitation and analyzed by
digestion with trypsin followed by two-
dimensional fractionation of the resulting
peptides [39]. (c) Bacterially expressed
GST–B-Myb was phosphorylated in vitro,
using immunopurified cyclin A–Cdk2, and
analyzed as described for B-Myb labeled in
vivo. (d) Swiss 3T3 fibroblasts synchronized
by serum starvation and readdition of serum
for 16 h were labeled for 5 h with 32P-labeled
orthophosphate. B-Myb was isolated by
immunoprecipitation and analyzed by
digestion with trypsin followed by two-
dimensional fractionation of the resulting
peptides, as described above. Radioactive
peptides were visualized with a
phosphorimage analyzer. The origin of each
fingerprint is at the lower left corner (marked
x). Electrophoresis was from left to right and
chromatography was from bottom to top. The
peptides marked with asterisks in (b,d)
comigrate with the major peptides labeled in
vitro, as determined by a mixing experiment
(data not shown).
endogenous B-Myb (by phosphate labeling) and thus
confirm and extend these results. To demonstrate that
endogenous B-Myb is phosphorylated at the same sites as
those phosphorylated in the presence of coexpressed
cyclin A, we performed two-dimensional tryptic phospho-
peptide mapping of endogenous B-Myb isolated from 32P-
orthophosphate-labeled Swiss 3T3 fibroblasts (Fig. 5d).
We observed a pattern of phosphopeptides similar to the
pattern obtained from ectopically expressed B-Myb
(compare Figs. 5d and 5b). Although the relative intensi-
ties of some of the phosphopeptide spots varied between
the two proteins, the fact that most of the phosphopep-
tides comigrated indicates that the slow-migrating form of
B-Myb induced by coexpression of cyclin A is phosphory-
lated at similar sites as endogenous B-Myb.
Discussion
Our results provide evidence that B-Myb, a conserved
member of the Myb transcription factor family, is regu-
lated directly by the cell-cycle machinery, and lead to a
major revision of the current view of B-Myb function.
Although previous work has suggested that B-Myb is an
inhibitory member of the Myb family [16,19], we have
now shown that B-Myb is a transactivating factor that is
regulated by its carboxy-terminal domain in a cell-cycle-
dependent manner.
Our findings highlight the central role of the carboxy-
terminal domain in the regulation of B-Myb activity. We
have shown that the inhibitory function of the carboxyl
terminus is counteracted by phosphorylation mediated by
cyclin A–Cdk2, suggesting that the carboxyl terminus of
B-Myb acts as a cell-cycle sensor. We have not yet
addressed in detail the mechanism by which the phospho-
rylation of B-Myb affects its transactivation activity. It is
clear, however, that the DNA-binding domain of B-Myb is
not required for cyclin-dependent regulation and, hence,
that phosphorylation does not simply regulate the DNA-
binding activity of the protein.
A second finding from our work is the identification of B-
Myb as a target for phosphorylation by cyclin A–Cdk2. We
have shown that the inhibition of B-Myb transactivation
activity by the carboxyl terminus is relieved specifically by
the action of cyclin A–Cdk2 and is accompanied by phos-
phorylation at multiple sites of the protein. Some of these
sites were also phosphorylated by cyclin A–Cdk2 in vitro,
suggesting that B-Myb is a direct substrate for the kinase.
At present, we do not know whether all of the sites that
showed cyclin A-induced phosphorylation are directly
phosphorylated by cyclin A–Cdk2. It is possible that, in
addition to direct phosphorylation by cyclin A–Cdk2,
other kinases acting on B-Myb are activated by cyclin
A–Cdk2, or that the initial phosphorylation of B-Myb by
cyclin A–Cdk2 alters the conformation of the B-Myb
protein in such a way that it becomes accessible to other
kinases. Nevertheless, a number of the phosphorylation
sites induced by cyclin A–Cdk2 are clearly recognized by
immunopurified cyclin A–Cdk2 in vitro, suggesting that
these sites are phosphorylated directly by cyclin A–Cdk2.
B-myb expression is regulated by the E2F transcription
factor and reaches maximum levels during the late G1 and
early S phases of the cell cycle [22,23], a time at which
cyclin A–Cdk2 becomes active as a kinase [3,5,7,8]. The
role of cyclin A–Cdk2 during S phase is as yet poorly under-
stood. Cyclin A–Cdk2 has been shown to phosphorylate
certain members of the E2F–DP transcription factor family,
thereby causing inhibition of their DNA-binding activity
during S phase [29–31]. By contrast to the inhibition of
E2F–DP, we show here that the transactivation potential of
B-Myb is increased by cyclin A–Cdk2. Our results therefore
provide evidence for a positive role of cyclin A–Cdk2 and
imply that B-Myb is a cell-cycle-regulated transcription
factor activated at the onset of S phase. The relevance of B-
Myb in cell proliferation is supported by the observation
that it is expressed in virtually all proliferating mammalian
cells [14–17,20,21], and that B-myb antisense oligonu-
cleotides inhibit cell proliferation [32,33]. Thus, B-Myb
appears to be an essential component of the machinery
which both controls transition from G1 to S phase and is reg-
ulated by cyclin A–Cdk2. Further analysis of this machin-
ery, in particular the identification of the genes that are
themselves regulated by B-Myb, might provide interesting
insights into the role of cyclin A–Cdk2 during S phase.
While this work was in progress, Sala et al. [34] have
shown that the transactivation potential of human B-Myb
is also increased upon coexpression of cyclins, in accor-
dance with the results described here. 
Conclusions
Cyclin A–Cdk2 is required during S phase of the cell cycle.
However, with the exception of the transcription factor
E2F, the activity of which is inhibited by cyclin A–Cdk2-
mediated phosphorylation, convincing protein targets for
cyclin A–Cdk2 have yet to be identified. It is therefore not
clear whether cyclin A–Cdk2 has other roles during S phase,
in addition to inhibiting E2F. The work presented here
leads to two major conclusions. First, it identifies B-Myb, a
highly conserved member of the Myb oncoprotein family,
as a target for cyclin A–Cdk2. Cyclin A–Cdk2-mediated
phosphorylation counteracts the effects of an inhibitory
domain located at the carboxyl terminus of B-Myb and
thereby increases the transactivation potential of B-Myb.
Our results, therefore, provide evidence for a positive role
of cyclin A–Cdk2. Second, our studies also shed new light
on the function of B-Myb. Although previous work has
suggested that B-Myb is an inhibitory member of the Myb
family, it now appears that B-Myb is a transactivating
factor that is regulated by phosphorylation of its carboxy-
terminal domain in a cell-cycle-dependent manner.
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Materials and methods
Expression vectors and transient transfection assays
Expression vectors for full-length mouse B-myb and GAL4–B-myb
have been described [20]. The vector encoding GAL4–B-Myb
carries a deletion of the B-myb coding region between an AgeI and a
HincII site; the deleted sequences encode the DNA-binding domain
of B-Myb. Expression vectors for B-Myb-D3, GAL4–B-Myb-D3 and B-
Myb-DPvu were generated by 3′ truncation of the B-Myb coding
region at ScaI (D3 truncations) or PvuII (DPvu truncation) sites. The
c-myb expression vector was obtained by cloning the complete
coding region of mouse c-myb into pCDNA3 (Invitrogen). Expression
vectors for human cyclins A, D1 and E were obtained from R. Wein-
berg. A kinase-negative mutant of Cdk2, Cdk2-R33, which has Lys33
mutated to arginine, was obtained from U. Deuschle and subcloned
into pCDNA3. The expression vector encoding the GAL4 DNA-
binding domain fused to the amino-terminal half of v-Myc,
pGAL4–Myc(Not), has been described [35]. COS-7 cells were trans-
fected as described [20]. The amounts of expression vectors given in
the figure legends were used for single 10 cm tissue culture dishes.
Transactivation activities were determined by transfecting each plate
with 5 mg of the Myb-responsive luciferase reporter gene p3xATk-Luc
[36] or the GAL4-responsive plasmid pG5E4-38Luc [20]. To correct
for differences in transfection efficiency, plates were cotransfected
with 0.5 mg of the b-galactosidase reporter gene pCMVb (Clontech).
Luciferase and b-galactosidase activities were determined as
described [20].
Western blotting, in vivo labeling and immunoprecipitations
B-Myb was detected by western blotting as described [20]. For
phosphate labeling, cells were pre-incubated in phosphate-free
medium (DMEM; ICN) for 30 min and then incubated with 32P-
orthophosphate (Amersham, carrier free) in phosphate-free medium at
100–400 mCi ml–1 for 5 h. For labeling with radioactive methionine,
the cells were incubated with 35S-methionine (Amersham;
> 800 Ci mmol–1) in methionine-free medium at 100 mCi ml–1 for 3 h.
Cells were washed with phosphate-buffered saline (PBS) and lysed in
1–2 ml lysis buffer (10 mM Tris-HCl, pH 7.8; 50 mM NaCl; 0.5%
NP40; 0.5% sodium deoxycholate; 0.1% SDS) per 10 cm tissue
culture plate. For phosphate-labeled cells, the lysis buffer was supple-
mented with 1 mM NaF and 0.5 mM sodium vanadate. The lysate was
sheared with a syringe, clarified and immunoprecipitated with serum
raised against the carboxyl terminus of mouse B-Myb [28] or with pre-
immune serum. Precipitates were collected using Staphylococcus
aureus (Pansorbin, Calbiochem) and washed three times with lysis
buffer. After boiling in 50 ml SDS sample buffer, the samples were
diluted into 1 ml lysis buffer, clarified and immunoprecipitated again,
this time using B-Myb serum raised against the DNA-binding domain
of mouse B-Myb [20], in order to reduce the background. Precipitates
were processed as described above and analyzed by 6% SDS–PAGE
and autoradiography. Transfected COS-7 cells were labeled and
immunoprecipitated as described above, except that only one
immunoprecipitation step (using antiserum against the B-Myb DNA-
binding domain) was performed.
Cell-cycle analysis
Swiss 3T3 cells were synchronized as described [37]. Synchronization
was verified by labeling the cells for 15 min with 5 mCi ml–1 3H-thymi-
dine (Amersham; 83 Ci mmol–1), followed by precipitation with 10%
trichloroacetic acid and counting of the incorporated radioactivity in a
liquid scintillation counter. Additionally, B-myb expression was analyzed
by northern blotting, as described [21]. 
In vitro kinase reaction
Human 293 cells overexpressing human cyclin A and Cdk2 were lysed
as described [37] and extracts immunoprecipitated using either anti-
Cdk2 or anti-cyclin A antibodies (Santa Cruz). Immunoprecipitates
were used to phosphorylate 5 mg bacterially expressed GST–B-Myb
(residues 227–704) as described [36].
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